SCHEMBL25758518

SCHEMBL25758518

C=C1Nc2cccc(Cl)c2C1(C)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.33
AKR1B1 P15121 1/20 0.33
HTR5A P47898 5/20 0.32
HTR1A P08908 4/20 0.32
HTR1D P28221 4/20 0.32
HTR2C P28335 4/20 0.32
HTR7 P34969 4/20 0.32
HTR2A P28223 2/20 0.32
HTR3A P46098 2/20 0.32
HTR6 P50406 1/20 0.32
HRH1 P35367 1/20 0.32
PDE7A Q13946 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
NFKB1 P19838 1/20 0.32
PNMT P11086 1/20 0.32
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758603 1.00 CES1 (0.33) CES1AKR1B1HTR5AHTR1AHTR1D
SCHEMBL25758610 0.82 AKR1B1 (0.33) AKR1B1
SCHEMBL25758522 0.82 AKR1B1 (0.33) AKR1B1
SCHEMBL25758649 0.81
SCHEMBL26177799 0.81
SCHEMBL23835845 0.79 AKR1B1 (0.42) CES1AKR1B1HTR6PDE7AHSD11B1
SCHEMBL23836086 0.79 AKR1B1 (0.42) CES1AKR1B1HTR6PDE7AHSD11B1
SCHEMBL25761384 0.76 PDE7A (0.35) CES1PDE7ACYP1A2CYP3A4CYP2D6
SCHEMBL26177795 0.76 PDE7A (0.35) CES1PDE7ACYP1A2CYP3A4CYP2D6
SCHEMBL25758570 0.74 PDK2 (0.41) AKR1B1HTR5AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230192663-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192663-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL CES1 198/4885AKR1B1 3400/4885HTR5A 4019/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV CES1 187/4885AKR1B1 3391/4885HTR5A 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.